FundingHealthcare & Life Sciences
Cent raises $5 Mn seed for early disease detection
By Abha Lohia · Editor ·
Cent: funding and every story →
seedFounded 2025
- Cent uses precision radiology and blood tests to detect life-threatening diseases before symptoms appear
- The company raised a $5 Mn seed round from OneFlow Holdings and South Park Commons, and exited stealth on 31 March 2026
- Cent has completed 1,500 scans, with 4% revealing critical conditions, and plans to expand to three cities from April 2026
What happened
- Cent, a preventive healthcare startup, launched on 31 March 2026 after coming out of stealth mode.
- The company raised a $5 Mn seed round from OneFlow Holdings and South Park Commons.
- Cent was founded by Shashank ND, cofounder of Practo, along with Anshul Khandelwal and Arpit Garg.
- The startup uses precision radiology and blood biomarkers to detect life-threatening diseases before symptoms appear.
- Cent has been operational since the beginning of FY2026-27 and has completed 1,500 scans.
- The company reported that 26% of scans found relevant clinical findings, and 4% found critical conditions.
- Cent's annualised revenue run rate is approximately $2 Mn, with 50% month-on-month growth.
- The startup plans to open centres in Mumbai, Delhi, and Bengaluru from April 2026, with Pune and Hyderabad later.
Why it matters
- Cent enters a growing market of preventive healthtech, with competitors like Biopeak also focusing on early detection.
- Biopeak raised $2.7 Mn in January 2026 to scale its clinic network, showing investor interest in this space.
- The startup's focus on detecting cancer, cardiac, neurological, and metabolic risks addresses a major healthcare gap.
- Cent's early traction, with 1,500 scans and 4% critical findings, highlights the potential impact of early detection.
- The founders' experience, especially Shashank ND's role at Practo, adds credibility to the venture.
The business
- Cent is a direct-to-consumer preventive healthcare intelligence platform.
- The company offers a diagnostic protocol including whole-body MRI, low-dose CT, DEXA scans, ECG, and 120+ blood and urine biomarkers.
- Cent uses AI-powered synthesis to analyse data and detect risks for cancer, cardiac, neurological, and metabolic conditions.
- The platform screens for 300+ conditions in a single visit, with faster scan times.
- Each assessment is followed by a clinical consultation.
- Cent operates single-purpose centres with a single workflow for disease detection.
- The company generates revenue from its diagnostic services, with an annualised run rate of about $2 Mn.
- Cent aims to help people live over 100 years by detecting diseases early.
The founders
SN
Shashank ND
Cofounder and CEO- Cofounder and CEO of Cent.
- Cofounder and CEO of Practo, a healthcare platform.
- His family office, OneFlow Holdings, invested in Cent's seed round.
AK
Anshul Khandelwal
Cofounder- Cofounder of Cent.
- Former Chief Marketing Officer at Ola, a ride-hailing company.
AG
Arpit Garg
Cofounder- Cofounder of Cent.
- Sales veteran with experience in the industry.
Who put in money
- OneFlow Holdings investor — Family office of Shashank ND, cofounder of Cent and Practo.
- South Park Commons investor — An investment firm that participated in the seed round.
In numbers
$5 MnSeed funding amount · 2026
1,500Scans completed · 2026
26%Scans with relevant findings · 2026
4%Scans with critical conditions · 2026
50%Month-on-month growth · 2026
$2 MnAnnualised revenue run rate · 2026
5,000Projected scans by year-end · 2026
What happens next
- Cent plans to build a network of single-purpose centres with a single workflow for CCNM detection.
- The company will start rolling out centres in Mumbai, Delhi, and Bengaluru from April 2026.
- Expansion to Pune and Hyderabad is planned for a later date.
Up against
Biopeak
Words to know
- Seed funding
- The first official round of financing for a startup, typically used to validate an idea and build a product.
- Stealth mode
- A strategy where a company keeps its operations and plans secret from competitors and the public until launch.
- Annualised revenue run rate
- An estimate of a company's future revenue over a year, based on current monthly or quarterly performance.
- Biomarkers
- Biological molecules in blood or other body fluids that indicate normal or abnormal processes, or disease.
The numbers around it
Cent has 2 funding rounds in StopDown's archive.
| When | Round | Amount | Led by |
|---|---|---|---|
| 27 October 2026 | Series A | $15M | Blume Ventures |
Healthcare & Life Sciences in March 2026: 16 rounds with a disclosed amount, $134 million in all; the biggest was Cult.fit (₹440 Cr ($47.2 Mn)). Every sector this year →
Other articles talking about it
Terms in this story
- Funding stage: Startups raise money in steps called funding stages: pre-seed, seed, Series A, B, C and later, ending in a listing or a sale. Each step is larger and asks for more proof. In India, Series A rounds run from a few million dollars to about $15 million, as of November 2026.
- Seed round: Pre-seed and seed are the first money a startup raises from outside investors. The difference is how much has been built when the cheque arrives: pre-seed backs an idea or prototype, usually with a cheque under ₹5 crore, while seed backs an early product and runs from a few crore rupees to a few million dollars.
Read next
FundingCent raises $15M for early disease detectionCent is a Bengaluru preventive healthcare startup that offers medical imaging and diagnostic checks to spot serious illness before symptoms appearFundingAugust AI raises $12M for US expansionAugust AI offers an AI health assistant that answers medical questions through WhatsApp and a mobile appFundingVitusCare raises $3 million Series BVitusCare runs dialysis units inside partner hospitals, which keeps costs low, and has grown from 22 to over 60 centres
Everything on Cent → · All startup news on 31 March 2026 →
Is this Cent? Get your “Featured on StopDown” badge →